CKLSF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -79.78 Med: 18.44 Max: 39.13
Current: -79.78
During the past 13 years, CK Life Sciences International Holdings's highest Return-on-Tangible-Equity was 39.13%. The lowest was -79.78%. And the median was 18.44%.
CKLSF's Return-on-Tangible-Equity is ranked worse than 67.03% of 1201
companies
in the Biotechnology industry
Industry Median: -42.4
vs CKLSF: -79.78
CK Life Sciences International Holdings (OTCPK:CKLSF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
CK Life Sciences International Holdings Return-on-Tangible-Equity Related Terms
CK Life Sciences International Holdings Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings Return-on-Tangible-Equity Chart
CK Life Sciences International Holdings Annual Data
CKLSF vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, CK Life Sciences International Holdings's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CK Life Sciences International Holdings Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CK Life Sciences International Holdings's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where CK Life Sciences International Holdings's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -23.64% mean?
CK Life Sciences International Holdings (CKLSF) has a Return-on-Tangible-Equity of -23.64% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on CK Life Sciences International Holdings and its competitors. According to the industry distribution chart, CK Life Sciences International Holdings ranks #805 out of 1201 companies in the Biotechnology industry, placing it in the top 67%.
Is CK Life Sciences International Holdings' Return-on-Tangible-Equity too high?
CK Life Sciences International Holdings' current Return-on-Tangible-Equity is -23.64%. Based on the distribution chart, CK Life Sciences International Holdings ranks #805 out of 1201 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CK Life Sciences International Holdings has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CK Life Sciences International Holdings ranks #805 out of 1201 companies for Return-on-Tangible-Equity. This places CK Life Sciences International Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on CK Life Sciences International Holdings and its competitors. CK Life Sciences International Holdings's current Return-on-Tangible-Equity is -23.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
CK Life Sciences International Holdings (CKLSF) has a current Return-on-Tangible-Equity of -23.64%. The stock's GF Value™ is $0.11, compared to a current price of $0.09 — trading 18.2% below its estimated fair value. The current Return-on-Tangible-Equity is -23.64%. CK Life Sciences International Holdings' overall GF Score™ is 39/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For CK Life Sciences International Holdings (CKLSF), the current Return-on-Tangible-Equity is -23.64% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CK Life Sciences International Holdings (CKLSF) Overvalued in 2026?
Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued.
The current stock price of $0.09 is trading 18.2% below its estimated GF Value™ of $0.11.
Key valuation signals for CKLSF:
Return-on-Tangible-Equity: -23.64%
GF Value™: $0.11 vs. price of $0.09 (18.2% below fair value)
No single metric tells the full story. See the CKLSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CK Life Sciences International Holdings Business Description
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
39GF Score
Get the complete analysis for CKLSF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CKLSF has been successfully added to your 
